<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345384</url>
  </required_header>
  <id_info>
    <org_study_id>005-201</org_study_id>
    <nct_id>NCT00345384</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients</brief_title>
  <official_title>Post-Operative Infusion of Low-Dose Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients: A Randomized, Double-Blind, Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, hemodynamic and respiratory
      stability of a low-dose of dexmedetomidine infusion in post-operative surgical in-patients
      undergoing thoracic surgery after discharge from PACU or ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine has sedative and analgesic properties that may reduce the opioid requirement
      in post-operative patients, thereby decreasing the chance of post-operative respiratory
      depression that occurs with opioid administration. In addition, patients may be more alert
      with less opioid medication. Currently, dexmedetomidine is not approved for use longer than
      twenty-four hours and must only be administered in the Intensive Care Unit where patients can
      be continuously monitored.

      This is a prospective, double-blinded, control group pilot study. One group (the control
      group) will receive a normal saline infusion and the second group (the treatment group) will
      receive low-dose Dexmedetomidine for up to 24 hours after they are admitted to an open
      nursing unit (not an Intensive Care Unit).

      During the surgery, the anesthesiologist will administer dexmedetomidine during the surgical
      procedure after an optional loading dose. All patients will receive pain medication using a
      Patient Controlled Analgesia (PCA) pump as per standard practice. In addition, if the
      physician deems necessary, an On-Q Pain Pump will deliver local anesthetic surrounding the
      incision under direction of the surgeon.

      Before discharge from the PACU or ICU, each subject will receive either low-dose
      dexmedetomidine or normal saline using a continuous infusion pump for up to 24 hours after
      the subject is discharged from either the PACU or the ICU to an open nursing unit. While on
      the open nursing unit patient vital signs, oxygen saturation, Ramsay score and pain score
      will recorded every two hours until the treatment drug is stopped.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Any Reduction in the Amount of Opioid Administered to Patients in the Dexmedetomidine Study Arm.</measure>
    <time_frame>An average of 24 hours, up to 30 hours per patient</time_frame>
    <description>To measure the amount of opioid use requested by patients enrolled in the dexmedetomidine study arm during the observation period of 24 hours, up to 30 hours per patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the Amount of Respiratory Depression in Each Groups</measure>
    <time_frame>Hours 6 to 16</time_frame>
    <description>Respiratory depression and deep levels of sedation can occur when morphine patient-controlled analgesia is prescribed for postoperative patients. In this secondary outcome measure, it was hypothesized that the addition of a dexmedetomidine infusion to the postoperative pain management protocol would reduce the amount of morphine delivered by a PCA pump while providing adequate analgesia. Data are reported for the time period 6 to 16 hours. However, the subjects were on the study for an average of 24 hours, up to 30 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Post-operative Pain</condition>
  <condition>Respiratory Depression</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine titrated over 24 hours</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex, Dexdor Titrated 0.1 to 0.5 ug.kg.h-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Normal Saline)</intervention_name>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) class I, II or III

          -  Undergoing thoracic surgery on an inpatient basis

          -  Age 18 up to 85 years of age

        Exclusion Criteria:

          -  Subject is pregnant and/or lactating

          -  Subject has a serious Central Nervous System (CNS)pathology/trauma that, per clinical
             judgment of the investigator, precludes responsiveness or survival.

          -  Subject for whom alpha-2 agonists are contraindicated

          -  Subject meets any of the following cardiovascular criteria:

          -  Acute unstable angina (defined during current hospital stay)

          -  Suspicion of acute myocardial infarction.

          -  Considered to have a left ventricular ejection fraction of less than 30%.Decision to
             exclude is predicated in the Investigator's opinion, and may be based on any
             combination of acute presentations, recently preformed diagnostic studies, or a
             history that suggests poor cardiac function. Pulmonary congestion of a non-cardiac
             origin or mild congestive failure primarily attributable to etiologies other than poor
             ventricular function are not exclusion criteria.

          -  Subject has participated in a trial with any experimental drug within 30 days prior to
             enrollment in the study, or has ever been enrolled in this study.

          -  Subject is unable to undergo any procedures required by the protocol.

          -  Subject has acute hepatitis, a history or presence of chronic hepatitis, and /or has
             had a positive result for Hepatitis B surface antigen test.

          -  Subject requires dialysis (e.g., hemodialysis, peritoneal dialysis, CVVHD).

          -  Subject has a known, uncontrolled seizure disorder.

          -  Subject has a known psychiatric illness that could confound a normal response to
             sedative treatment.

          -  Subject is terminally ill with a life duration expectancy of &lt; 60 days.

          -  Subject has a history of Obstructive Sleep Apnea.

          -  Oxygen saturation is &lt; 90% on room air.

          -  Subject is on beta blocker medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Ramsay, MD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor University Medical Center - Department of Anesthesiology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2006</study_first_posted>
  <results_first_submitted>August 10, 2011</results_first_submitted>
  <results_first_submitted_qc>July 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2015</results_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Sedation</keyword>
  <keyword>Opioid</keyword>
  <keyword>Respiratory depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants will be recruited from the from the BUMC Operating Room schedule prior to their procedure. Informed consent will be obtained in a secure area. Recruitment will continue until goal reached.</recruitment_details>
      <pre_assignment_details>Participants were required to be between the ages of 18-85 and receiving general anesthesia with an AMerican Society of Anesthesiologists score of three or less, and undergoing thoracotomy surgery. Liver and renal failure patients were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Saline</title>
          <description>Blinded Normal saline infusion titrated as if study drug</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine</title>
          <description>Received Dexmedetomidine for 24 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>13 were withdrawn from study prior to initiation of drug due to exclusion criteria that required an overnight stay in Recovery or ICU.</population>
      <group_list>
        <group group_id="B1">
          <title>Normal Saline</title>
          <description>Standard of care</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine</title>
          <description>titrated IV for 24 hours post ICU</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12.8"/>
                    <measurement group_id="B2" value="61" spread="10.75"/>
                    <measurement group_id="B3" value="60" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure Any Reduction in the Amount of Opioid Administered to Patients in the Dexmedetomidine Study Arm.</title>
        <description>To measure the amount of opioid use requested by patients enrolled in the dexmedetomidine study arm during the observation period of 24 hours, up to 30 hours per patient.</description>
        <time_frame>An average of 24 hours, up to 30 hours per patient</time_frame>
        <population>Participants completing the study were analyzed as per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patient group to receive placebo (saline).</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>Patient group to receive Dexmedetomidine.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Any Reduction in the Amount of Opioid Administered to Patients in the Dexmedetomidine Study Arm.</title>
          <description>To measure the amount of opioid use requested by patients enrolled in the dexmedetomidine study arm during the observation period of 24 hours, up to 30 hours per patient.</description>
          <population>Participants completing the study were analyzed as per protocol</population>
          <units>IV morphine equivalency in mg</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morphine equivalency administered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="14" upper_limit="84"/>
                    <measurement group_id="O2" value="29" lower_limit="3" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted for total time on study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="17" upper_limit="91"/>
                    <measurement group_id="O2" value="35" lower_limit="7" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Precentage Difference</param_type>
            <param_value>41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The percentage in opioid use by the dexmedetomidine group in comparison to the placebo for the period of time on study drug is calculated as follows: numerator = 29, denominator = 49.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage difference</param_type>
            <param_value>35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>A measure of opioid use, weighted for total time on study drug. This is examined by a comparison of the dexmedetomidine group to the placebo group: numerator = 35, denominator = 54.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure the Amount of Respiratory Depression in Each Groups</title>
        <description>Respiratory depression and deep levels of sedation can occur when morphine patient-controlled analgesia is prescribed for postoperative patients. In this secondary outcome measure, it was hypothesized that the addition of a dexmedetomidine infusion to the postoperative pain management protocol would reduce the amount of morphine delivered by a PCA pump while providing adequate analgesia. Data are reported for the time period 6 to 16 hours. However, the subjects were on the study for an average of 24 hours, up to 30 hours.</description>
        <time_frame>Hours 6 to 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Control group to receive a normal saline infusion, set at a rate as if it were the active drug.</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>Study group to receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 30 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
Dexmedetomidine: Dexmedetomidine titrated over 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Measure the Amount of Respiratory Depression in Each Groups</title>
          <description>Respiratory depression and deep levels of sedation can occur when morphine patient-controlled analgesia is prescribed for postoperative patients. In this secondary outcome measure, it was hypothesized that the addition of a dexmedetomidine infusion to the postoperative pain management protocol would reduce the amount of morphine delivered by a PCA pump while providing adequate analgesia. Data are reported for the time period 6 to 16 hours. However, the subjects were on the study for an average of 24 hours, up to 30 hours.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="9"/>
                    <measurement group_id="O2" value="42" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-value reported in this table corresponds with the 6 to 16 hour time frame.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week from initiation of study drug.</time_frame>
      <desc>0 serious adverse events were detected in patients enrolled in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline Group</title>
          <description>Normal saline infused at calculated rate as if it were study drug</description>
        </group>
        <group group_id="E2">
          <title>Study Drug Group</title>
          <description>Dexmedetomidine titrated IV from 0.1 microgram/kg/h upto 0.5 microgram/kg/h to control pain for 24 hours post ICU</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>systolic BP &lt; 90 Mm Hg</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>heart rate &lt; 50 bpm</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tacycardia</sub_title>
                <description>Heart rate &gt; 110 bpm</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot study with small numbers of participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>President Baylor Research Institute</name_or_title>
      <organization>Baylor Research Institute</organization>
      <phone>214-820-3296</phone>
      <email>researchclinicaltrials@baylorhealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

